Firefly Neuroscience and Next Health Launch Precision Cognitive Health Platform Following FDA Advisory Committee Recommendation on Neuroprotective Peptides
核心洞察
Firefly Neuroscience (搜索) and Next Health (搜索) announced a strategic partnership to launch a precision cognitive health platform integrating AI-powered EEG/ERP brain biomarker technology with personalized cognitive peptide protocols.
The collaboration follows an FDA Advisory Committee recommendation to add six therapeutic peptides, including Epitalon and Semax, to the list of bulk drug substances eligible for pharmacy compounding.
The initiative aims to replace subjective cognitive assessments with objective, data-driven clinical decision-making using Firefly's FDA 510(k)-cleared Evoke System.
Firefly Neuroscience (搜索), Inc. (NASDAQ: AIFF) and Next Health (搜索) announced on July 28, 2026 a strategic partnership to launch a novel precision cognitive health platform that integrates Firefly's AI-powered, FDA-cleared EEG/ERP brain biomarker technology with personalized cognitive peptide protocols. The initiative, which aims to provide physicians with objective measures of brain function to help personalize, monitor, and optimize emerging cognitive therapies, comes on the heels of a significant regulatory development.
Late last week, an FDA Advisory Committee voted to recommend adding six therapeutic peptides—including Epitalon and Semax—to the list of bulk drug substances eligible for pharmacy compounding. While the recommendation is not binding and requires further FDA action, it represents an important regulatory milestone that could broaden physician access to these emerging peptide therapies.
The Science Behind Epitalon and Semax
Epitalon and Semax have each drawn growing attention in the scientific literature for their potential neuroprotective and cognitive-supportive properties. Epitalon, a pineal tetrapeptide, has been the subject of research exploring its bioactive properties, as documented in a 2025 review published in the International Journal of Molecular Sciences. Semax has been studied for its potential in addressing pathological impairments, including research published in Acta Naturae examining its effects in an animal model of Alzheimer's disease (搜索).
Both peptides remain investigational. Neither Epitalon nor Semax is approved by the FDA for any use, and the Advisory Committee's recommendation addresses only compounding eligibility—it does not constitute an FDA determination regarding the safety or efficacy of either peptide.
Integrating Objective Biomarkers with Peptide Protocols
The collaboration seeks to replace subjective assessments of cognitive health with data-driven clinical decision-making by combining objective EEG-based biomarkers with personalized therapeutic protocols. Firefly's proprietary database now consists of over 200,000 EEG/ERP brain scans, described as the world's largest known standardized EEG/ERP repository. Its EEG-based, AI-driven, and FDA 510(k)-cleared Evoke System has potential applications across conditions such as depression (搜索), dementia (搜索), anxiety disorders, concussions, ADHD (搜索), and PTSD (搜索).
"Founded over a decade ago, Next Health (搜索) pioneered the clinical longevity category before longevity was a mainstream concept," said Greg Lipschitz, Firefly's Chief Executive Officer. "Today, it is the globally recognized leader in biomarker-driven, proactive health optimization, operating with a trusted consumer brand, extensive provider network, and clinical infrastructure that took more than a decade to build. Likewise, we believe Firefly has established a differentiated position through our FDA 510(k)-cleared, AI-powered EEG/ERP platform."
Lipschitz emphasized that unlike traditional symptom-based approaches, Firefly provides objective neurological biomarkers that can guide treatment decisions. "As new peptide therapies, like Epitalon and Semax, continue to capture global attention, and as interest in objective brain health measurement and cognitive therapeutics accelerates, we believe combining Firefly's quantitative brain biomarkers with Next Health (搜索)'s clinical expertise has the potential to redefine how cognitive health is measured, personalized, and monitored."
A Data-Driven Approach to Longevity Medicine
Dr. Darshan Shah, Founder and Chief Executive Officer of Next Health (搜索), described the company as representing "the vanguard of the longevity revolution—where cutting-edge medical technology, luxury hospitality, and proactive health optimization converge to redefine the future of wellness."
"Our comprehensive functional medicine approach to health is data-driven and defined by not merely the absence of disease, but the abundance of vitality," Dr. Shah commented. "Firefly's FDA-cleared brain wave analytics technology complements that by enabling clinicians to objectively measure brain function before, during and after treatment. Objective brain mapping has the potential to become an important component of personalized cognitive medicine, helping clinicians better understand, personalize, and monitor emerging peptide therapies."
Implementation and Future Milestones
The initiative is expected to leverage Next Health (搜索)'s rapidly expanding network of longevity clinics. Next Health operates with a Medicine 4.0 model combining diagnostics, longevity therapies, and preventative medicine, offering services including precision IV therapy, biomarker testing, regenerative and peptide therapies, and advanced treatments such as ozone therapy and therapeutic plasma exchange.
The companies intend to collaborate on developing standardized clinical protocols integrating Firefly's FDA-cleared EEG/ERP platform with provider-guided peptide therapies and expect to provide updates as key milestones are achieved. The collaboration establishes a scalable framework for integrating objective brain biomarker assessments into routine longevity and cognitive care, helping lay the foundation for broader adoption of quantitative neurodiagnostics in precision medicine.